Loading…

O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005

BackgroundLittle is known about the epidemiology of multidrug resistant tuberculous meningitis (TBM), defined as resistance to at least isoniazid and rifampin. We sought to describe cases of multidrug resistant TBM reported in the United States with respect to clinical characteristics and treatment...

Full description

Saved in:
Bibliographic Details
Published in:Journal of epidemiology and community health (1979) 2011-08, Vol.65 (Suppl 1), p.A19-A19
Main Authors: Vinnard, C, Winston, C, Wileyto, E P, MacGregor, R R, Bisson, G
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A19
container_issue Suppl 1
container_start_page A19
container_title Journal of epidemiology and community health (1979)
container_volume 65
creator Vinnard, C
Winston, C
Wileyto, E P
MacGregor, R R
Bisson, G
description BackgroundLittle is known about the epidemiology of multidrug resistant tuberculous meningitis (TBM), defined as resistance to at least isoniazid and rifampin. We sought to describe cases of multidrug resistant TBM reported in the United States with respect to clinical characteristics and treatment outcomes.MethodsWe conducted a retrospective cohort study using data collected by the National Tuberculosis Surveillance System at the Centers for Disease Control and Prevention in the United States. We included patients diagnosed with TBM between 1 January 1993 and 31 December 2005, with a positive culture from cerebrospinal fluid and drug susceptibility testing performed. We compared clinical and demographic characteristics of TBM patients with and without multidrug resistance, as well as the proportion of patients in each group that died while still receiving anti-tuberculosis therapy.Results26 of 1683 patients (1.5%) with cerebrospinal fluid culture-positive TBM were found to have multidrug resistance on initial susceptibility testing. Anti-tuberculosis therapy was stopped due to death in 19 of 26 patients (73%), after a median of 42 days of treatment (IQR 15–225). Of the 19 patients with known HIV status, 17 were HIV-positive (89%).DiscussionMost cases of multidrug resistant TBM in the United States occurred in HIV-infected patients, and the associated mortality was high. Due to the time period required to obtain drug susceptibility results based on conventional methods, rapid molecular diagnosis of drug resistance is of great potential benefit in this setting and needs to be evaluated further.
doi_str_mv 10.1136/jech.2011.142976a.46
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1171885512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1171885512</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2306-ac27b5058b25e22aa519f133257d44ae68235c89764ee28d84b50e20abf325443</originalsourceid><addsrcrecordid>eNqNkLuOEzEUhi0EEiHwBhQj0VAwWZ_j20wJWW5SNpGAIDrLMznZOEwmWdsjQZeGJ-AN90lwlIiCiuq4-P7_HH-MPQc-ARD6akvtZoIcYAISa6PdROoHbATS8BKNqB6yEQcpSs7Vt8fsSYxbnp8G6xFbLrDMsfvjr5uhS34VhtsiUPQxuT4VaWgotEO3H2Kxo973tz75WPi-SBsqlr1PtCo-J5coviqgrsX98Tfm6qfs0dp1kZ5d5pgt3739Mv1QzhbvP05fz8oGBdela9E0iquqQUWIzimo1yAEKrOS0pGuUKi2yj-SRFitKplpQu6adWakFGP28tx7CPu7gWKyOx9b6jrXU77ZAhioKqUAM_riH3S7H0Kfr7NgTI1GK3UqlGeqDfsYA63tIfidCz8tcHtybU-u7cm1vbi2UudYeY5lb_Tjb8aF71YbYZSdf53aa67fqJtPMzvP_NWZb3bb_9vwB1I1jwI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779276554</pqid></control><display><type>article</type><title>O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>BMJ Journals</source><creator>Vinnard, C ; Winston, C ; Wileyto, E P ; MacGregor, R R ; Bisson, G</creator><creatorcontrib>Vinnard, C ; Winston, C ; Wileyto, E P ; MacGregor, R R ; Bisson, G</creatorcontrib><description>BackgroundLittle is known about the epidemiology of multidrug resistant tuberculous meningitis (TBM), defined as resistance to at least isoniazid and rifampin. We sought to describe cases of multidrug resistant TBM reported in the United States with respect to clinical characteristics and treatment outcomes.MethodsWe conducted a retrospective cohort study using data collected by the National Tuberculosis Surveillance System at the Centers for Disease Control and Prevention in the United States. We included patients diagnosed with TBM between 1 January 1993 and 31 December 2005, with a positive culture from cerebrospinal fluid and drug susceptibility testing performed. We compared clinical and demographic characteristics of TBM patients with and without multidrug resistance, as well as the proportion of patients in each group that died while still receiving anti-tuberculosis therapy.Results26 of 1683 patients (1.5%) with cerebrospinal fluid culture-positive TBM were found to have multidrug resistance on initial susceptibility testing. Anti-tuberculosis therapy was stopped due to death in 19 of 26 patients (73%), after a median of 42 days of treatment (IQR 15–225). Of the 19 patients with known HIV status, 17 were HIV-positive (89%).DiscussionMost cases of multidrug resistant TBM in the United States occurred in HIV-infected patients, and the associated mortality was high. Due to the time period required to obtain drug susceptibility results based on conventional methods, rapid molecular diagnosis of drug resistance is of great potential benefit in this setting and needs to be evaluated further.</description><identifier>ISSN: 0143-005X</identifier><identifier>EISSN: 1470-2738</identifier><identifier>DOI: 10.1136/jech.2011.142976a.46</identifier><identifier>CODEN: JECHDR</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Drug resistance ; Epidemiology ; Human immunodeficiency virus ; Mycobacterium ; Tuberculosis</subject><ispartof>Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A19-A19</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jech.bmj.com/content/65/Suppl_1/A19.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jech.bmj.com/content/65/Suppl_1/A19.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>112,113,314,780,784,3194,27924,27925,77594,77595</link.rule.ids></links><search><creatorcontrib>Vinnard, C</creatorcontrib><creatorcontrib>Winston, C</creatorcontrib><creatorcontrib>Wileyto, E P</creatorcontrib><creatorcontrib>MacGregor, R R</creatorcontrib><creatorcontrib>Bisson, G</creatorcontrib><title>O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005</title><title>Journal of epidemiology and community health (1979)</title><addtitle>J Epidemiol Community Health</addtitle><description>BackgroundLittle is known about the epidemiology of multidrug resistant tuberculous meningitis (TBM), defined as resistance to at least isoniazid and rifampin. We sought to describe cases of multidrug resistant TBM reported in the United States with respect to clinical characteristics and treatment outcomes.MethodsWe conducted a retrospective cohort study using data collected by the National Tuberculosis Surveillance System at the Centers for Disease Control and Prevention in the United States. We included patients diagnosed with TBM between 1 January 1993 and 31 December 2005, with a positive culture from cerebrospinal fluid and drug susceptibility testing performed. We compared clinical and demographic characteristics of TBM patients with and without multidrug resistance, as well as the proportion of patients in each group that died while still receiving anti-tuberculosis therapy.Results26 of 1683 patients (1.5%) with cerebrospinal fluid culture-positive TBM were found to have multidrug resistance on initial susceptibility testing. Anti-tuberculosis therapy was stopped due to death in 19 of 26 patients (73%), after a median of 42 days of treatment (IQR 15–225). Of the 19 patients with known HIV status, 17 were HIV-positive (89%).DiscussionMost cases of multidrug resistant TBM in the United States occurred in HIV-infected patients, and the associated mortality was high. Due to the time period required to obtain drug susceptibility results based on conventional methods, rapid molecular diagnosis of drug resistance is of great potential benefit in this setting and needs to be evaluated further.</description><subject>Drug resistance</subject><subject>Epidemiology</subject><subject>Human immunodeficiency virus</subject><subject>Mycobacterium</subject><subject>Tuberculosis</subject><issn>0143-005X</issn><issn>1470-2738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkLuOEzEUhi0EEiHwBhQj0VAwWZ_j20wJWW5SNpGAIDrLMznZOEwmWdsjQZeGJ-AN90lwlIiCiuq4-P7_HH-MPQc-ARD6akvtZoIcYAISa6PdROoHbATS8BKNqB6yEQcpSs7Vt8fsSYxbnp8G6xFbLrDMsfvjr5uhS34VhtsiUPQxuT4VaWgotEO3H2Kxo973tz75WPi-SBsqlr1PtCo-J5coviqgrsX98Tfm6qfs0dp1kZ5d5pgt3739Mv1QzhbvP05fz8oGBdela9E0iquqQUWIzimo1yAEKrOS0pGuUKi2yj-SRFitKplpQu6adWakFGP28tx7CPu7gWKyOx9b6jrXU77ZAhioKqUAM_riH3S7H0Kfr7NgTI1GK3UqlGeqDfsYA63tIfidCz8tcHtybU-u7cm1vbi2UudYeY5lb_Tjb8aF71YbYZSdf53aa67fqJtPMzvP_NWZb3bb_9vwB1I1jwI</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Vinnard, C</creator><creator>Winston, C</creator><creator>Wileyto, E P</creator><creator>MacGregor, R R</creator><creator>Bisson, G</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7QL</scope><scope>7TK</scope><scope>C1K</scope></search><sort><creationdate>20110801</creationdate><title>O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005</title><author>Vinnard, C ; Winston, C ; Wileyto, E P ; MacGregor, R R ; Bisson, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2306-ac27b5058b25e22aa519f133257d44ae68235c89764ee28d84b50e20abf325443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Drug resistance</topic><topic>Epidemiology</topic><topic>Human immunodeficiency virus</topic><topic>Mycobacterium</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vinnard, C</creatorcontrib><creatorcontrib>Winston, C</creatorcontrib><creatorcontrib>Wileyto, E P</creatorcontrib><creatorcontrib>MacGregor, R R</creatorcontrib><creatorcontrib>Bisson, G</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of epidemiology and community health (1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vinnard, C</au><au>Winston, C</au><au>Wileyto, E P</au><au>MacGregor, R R</au><au>Bisson, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005</atitle><jtitle>Journal of epidemiology and community health (1979)</jtitle><addtitle>J Epidemiol Community Health</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>65</volume><issue>Suppl 1</issue><spage>A19</spage><epage>A19</epage><pages>A19-A19</pages><issn>0143-005X</issn><eissn>1470-2738</eissn><coden>JECHDR</coden><abstract>BackgroundLittle is known about the epidemiology of multidrug resistant tuberculous meningitis (TBM), defined as resistance to at least isoniazid and rifampin. We sought to describe cases of multidrug resistant TBM reported in the United States with respect to clinical characteristics and treatment outcomes.MethodsWe conducted a retrospective cohort study using data collected by the National Tuberculosis Surveillance System at the Centers for Disease Control and Prevention in the United States. We included patients diagnosed with TBM between 1 January 1993 and 31 December 2005, with a positive culture from cerebrospinal fluid and drug susceptibility testing performed. We compared clinical and demographic characteristics of TBM patients with and without multidrug resistance, as well as the proportion of patients in each group that died while still receiving anti-tuberculosis therapy.Results26 of 1683 patients (1.5%) with cerebrospinal fluid culture-positive TBM were found to have multidrug resistance on initial susceptibility testing. Anti-tuberculosis therapy was stopped due to death in 19 of 26 patients (73%), after a median of 42 days of treatment (IQR 15–225). Of the 19 patients with known HIV status, 17 were HIV-positive (89%).DiscussionMost cases of multidrug resistant TBM in the United States occurred in HIV-infected patients, and the associated mortality was high. Due to the time period required to obtain drug susceptibility results based on conventional methods, rapid molecular diagnosis of drug resistance is of great potential benefit in this setting and needs to be evaluated further.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><doi>10.1136/jech.2011.142976a.46</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0143-005X
ispartof Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A19-A19
issn 0143-005X
1470-2738
language eng
recordid cdi_proquest_miscellaneous_1171885512
source JSTOR Archival Journals and Primary Sources Collection; BMJ Journals
subjects Drug resistance
Epidemiology
Human immunodeficiency virus
Mycobacterium
Tuberculosis
title O2-1.1 Multidrug resistant tuberculous meningitis in the United States, 1993–2005
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A16%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=O2-1.1%E2%80%85Multidrug%20resistant%20tuberculous%20meningitis%20in%20the%20United%20States,%201993%E2%80%932005&rft.jtitle=Journal%20of%20epidemiology%20and%20community%20health%20(1979)&rft.au=Vinnard,%20C&rft.date=2011-08-01&rft.volume=65&rft.issue=Suppl%201&rft.spage=A19&rft.epage=A19&rft.pages=A19-A19&rft.issn=0143-005X&rft.eissn=1470-2738&rft.coden=JECHDR&rft_id=info:doi/10.1136/jech.2011.142976a.46&rft_dat=%3Cproquest_cross%3E1171885512%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b2306-ac27b5058b25e22aa519f133257d44ae68235c89764ee28d84b50e20abf325443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1779276554&rft_id=info:pmid/&rfr_iscdi=true